Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicaid Reform Bill Is A Draw For Pharma; Pharmacy Continues Its Fight

Executive Summary

The conference report on budget reconciliation creates a new definition of the Medicaid federal upper limit for pharmacy reimbursement for multiple source drugs
Advertisement

Related Content

Medicaid AMPs May Include More PBM Discounts, If CMS Can Figure Out How
McKesson Denies Role In Setting First DataBank AWPs
AstraZeneca Rides Wave Of Crestor Data; Is Pfizer Facing Lipitor Wipeout?
Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned
Too Much Leeway? OIG Gives CMS Broad Advice For Medicaid Pricing Reg
Year of the authorized generic
Senate Medicaid Reform Bill Could Mean More Whistleblowers At State Level
Authorized Generics’ Impact On Medicaid Pricing To Be Focus Of HHS Study
CMS Drug Pricing Guidance Proposed In Medicaid Commission Report
CMS Drug Pricing Guidance Proposed In Medicaid Commission Report
Advertisement
UsernamePublicRestriction

Register

PS046712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel